MRC1 and small cell lung carcinoma: Furthermore, while our findings suggest enhanced sensitivity to immune checkpoint inhibitors in MMR-deficient SCLC, further studies are needed to validate our findings and assess potential toxicities of such a therapeutic approach and evaluate the long-term efficacy and potential resistance mechanisms in a clinical setting.